Related Experiment Videos
[Herpes encephalitis in newborn infants. Retrospective study of 12 cases]
J Bigotte1, J C Mselati, M C Routon
1Service de Pédiatrie, Centre hospitalier d'Orsay.
Insights
Early treatment of neonatal herpes simplex virus (HSV) infection is crucial. This study found no dose-dependent difference in acyclovir efficacy, suggesting early intervention is key for better outcomes in neonatal HSV disease.
Area of Science:
- Neonatal infectious diseases
- Virology
- Pediatric pharmacology
Background:
Herpes simplex virus (HSV) may cause severe disease in neonates with high mortality and devastating sequelae. Adenine arabinoside (ara-A) and acyclovir can be effective in treating the neonatal disseminated disease, but optimal doses of the drugs are still debated.
Patients:
The files of 12 neonates treated for HSV infection between May 1983 and April 1989 in 9 departments of pediatrics were studied. The following data were analysed: age at initial signs, clinical manifestations, CSF abnormalities, viral and immunological studies, imaging techniques used to detect brain damage, doses and duration of treatment.
Results:
The mean age at the first infectious signs was 12.3 +/- 9.3 days and neurological manifestations were first seen at 18.3 +/- 7.7 days. Acyclovir was given intravenously for 2 to 4 weeks at doses of 30 mg/kg/24 hr (5 patients) or 60 mg/kg/24 hr (7 patients) at an average of 7.7 days after the first clinical manifestations. The initial dose of 30 mg/kg/24 hr was increased to 50 or 60 mg/kg/24 hr in 3 patients. Five patients died during treatment, and 5 had severe sequelae; follow-up for the 2 remaining patients was not possible. There was no correlation between prognosis and the dose of acyclovir, which was well tolerated in all patients.
Conclusions:
The best results are obtained when treatment is started early. This retrospective study failed to show any dose-dependent difference in the efficacy of acyclovir. A prospective study with different doses would be useful.